The effect of long-term verapamil treatment on the secretion of cortisol and aldosterone in subjects with normal and high blood pressure.
Based on their previous observations of the stimulating action of verapamil on the secretory reserve of cortisol after one-week oral administration to healthy volunteers, the author investigated the effect of this calcium entry blocker on the adrenocortical function (cortisol and aldosterone secretion) during therapeutic administration to patients with mild arterial hypertension and normotensive patients suffering from Raynaud's syndrome. Verapamil, 3-4 X 80 mg per day by the oral route, did not lead to significant changes of cortisol levels at rest nor after ACTH stimulation when assessed at the end of the first month of treatment in both groups. However, normotensive subjects with Raynaud's syndrome showed a decline of ACTH stimulated cortisolaemia during the 3rd month (p less than 0.05) and 4th month (p less than 0.01) and a reduction of cortisol secretory reserve (delta cortisol) during the 3rd month of treatment (p less than 0.05). In aldosterone secretion of normotensives with Raynaud's syndrome no significant changes were observed. In hypertensive subjects, the decline of ACTH stimulated cortisolaemia at the end of the 3rd and 4th month was not significant and delta cortisol did not change. The initial aldosterone levels before and after ACTH and delta aldosterone before treatment of hypertensives was lower as compared with normotensives (p less than 0.01, p less than 0.01 and p less than 0.05, respectively), and increased gradually during treatment in the 4th month significantly (p less than 0.05, p less than 0.01 and p less than 0.01, respectively). The hypotensive effect of verapamil persisted throughout the treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
Zofková
I
I
D000302:Adrenal Cortex / Q000187:drug effects / Q000378:metabolism; D000324:Adrenocorticotropic Hormone; D000328:Adult; D000450:Aldosterone / Q000378:metabolism*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011928:Raynaud Disease / Q000188:drug therapy; D013997:Time Factors; D014700:Verapamil / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
D000450:Aldosterone; D000324:Adrenocorticotropic Hormone; D014700:Verapamil; D006854:Hydrocortisone